A carregar...
Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2‐Amplified Colorectal Cancer
Human epidermal growth factor 2 (HER2) amplification represents a distinct molecular subgroup of colorectal cancers that is associated with anti‐epidermal growth factor receptor resistance and sensitivity to dual HER2 targeting. Although clinical trials have reported activity for trastuzumab/pertuzu...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5896709/ https://ncbi.nlm.nih.gov/pubmed/29330210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0436 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|